Shin, Sang Joon

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 245

YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma

Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersHippo pathway signaling and YAP/TAZ

Cited by 241

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 138

Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors

Kim, H. S., Shin, S. J., Kim, S. C., An, S., Rha, S. Y., Ahn, J. B., Cho, B. C., Choi, H. J., Sohn, J. H., Kim, H. S., et al. (2013) · Supportive Care in Cancer

Pain Management and Opioid UseCancer survivorship and care

Cited by 47

Continuous multimodal data supply chain and expandable clinical decision support for oncology

Chang, J. S., Kim, H., Baek, E. S., Choi, J. E., Lim, J. S., Kim, J. S., & Shin, S. J. (2025) · npj Digital Medicine

Electronic Health Records SystemsArtificial Intelligence in Healthcare and Education

Cited by 26

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

Kim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 21